The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Mkhitaryan E.A.

Russian Clinical and Research Center of Gerontology — Pirogov Russian National Research Medical University

Fateeva V.V.

Russian Clinical and Research Center of Gerontology — Pirogov Russian National Research Medical University

Kamchatnov P.R.

Pirogov Russian National Research Medical University

Cerebral amyloid angiopathy

Authors:

Mkhitaryan E.A., Fateeva V.V., Kamchatnov P.R.

More about the authors

Read: 2622 times


To cite this article:

Mkhitaryan EA, Fateeva VV, Kamchatnov PR. Cerebral amyloid angiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(2):85‑90. (In Russ.)
https://doi.org/10.17116/jnevro202412402185

Recommended articles:
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16
Gender aspe­cts of atte­ntion defi­cit hype­ractivity diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):70-75
Rela­tionship between stroke-associated pneumonia and long-term outcomes of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):57-61
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Cognitive impairment after major surgical operations. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):74-80

References:

  1. Miller-Thomas MM, Sipe AL, Benzinger TL, et al. Multimodality Review of Amyloid-related Diseases of the Central Nervous System. Radiographics. 2016;36(4):1147-1163. https://doi.org/10.1148/rg.2016150172
  2. Boulouis G, Charidimou A, Greenberg SM. Sporadic Cerebral Amyloid Angiopathy: Pathophysiology, Neuroimaging Features, and Clinical Implications. Semin Neurol. 2016;36(3):233-243.  https://doi.org/10.1055/s-0036-1581993
  3. Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol. 2011;70(6):871-880.  https://doi.org/10.1002/ana.22516
  4. Jäkel L, De Kort AM, Klijn CJM, et al. Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. Alzheimers Dement. 2022;18(1):10-28.  https://doi.org/10.1002/alz.12366
  5. Makotrova TA, Levin OS, Arablinskiĭ AV. Cerebral amyloid angiopathy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114(6-2):87-93. (In Russ.).
  6. Attems J, Jellinger K, Thal DR, Van Nostrand W. Review: sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2011;37(1):75-93.  https://doi.org/10.1111/j.1365-2990.2010.01137.x
  7. Singh B, Lavezo J, Gavito-Higueroa J, et al. Updated Outlook of Cerebral Amyloid Angiopathy and Inflammatory Subtypes: Pathophysiology, Clinical Manifestations, Diagnosis and Management. J Alzheimers Dis Rep. 2022;6(1):627-639. 
  8. Hall CN, Reynell C, Gesslein B, et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. 2014;508(7494):55-60.  https://doi.org/10.1038/nature13165
  9. Mann DMA, Davidson YS, Robinson AC, et al. Patterns and severity of vascular amyloid in Alzheimer’s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer’s disease. Acta Neuropathol. 2018;136(4):569-587.  https://doi.org/10.1007/s00401-018-1866-3
  10. Bellenguez C, Küçükali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet. 2022;54(4):412-436.  https://doi.org/10.1038/s41588-022-01024-z
  11. Yamada M. Cerebral amyloid angiopathy: emerging concepts. J Stroke. 2015;17(1):17-30.  https://doi.org/10.5853/jos.2015.17.1.17
  12. Carnevale D, Mascio G, D’Andrea I, et al. Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension. 2012;60(1):188-197.  https://doi.org/10.1161/HYPERTENSIONAHA.112.195511
  13. Yamada M, Hamaguchi T, Sakai K. Acquired cerebral amyloid angiopathy: An emerging concept. Prog Mol Biol Transl Sci. 2019;168:85-95.  https://doi.org/10.1016/bs.pmbts.2019.05.012
  14. Banerjee G, Samra K, Adams ME, et al. Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon. J Neurol Neurosurg Psychiatry. 2022;74(7):328792. https://doi.org/10.1136/jnnp-2022-328792
  15. Rabin JS, Nichols E, La Joie R, et al. Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline. Brain. 2022;145(8):2823-2833. https://doi.org/10.1093/brain/awac178
  16. Malhotra K, Theodorou A, Katsanos AH, et al. Prevalence of Clinical and Neuroimaging Markers in Cerebral Amyloid Angiopathy: A Systematic Review and Meta-Analysis. Stroke. 2022;53(6):1944-1953. https://doi.org/10.1161/STROKEAHA.121.035836
  17. Charidimou A, Boulouis G, Gurol ME, et al. Emerging concepts in sporadic cerebral amyloid angiopathy. Brain. 2017;140(7):1829-1850. https://doi.org/10.1093/brain/awx047
  18. Boyle PA, Yu L, Nag S, et al. Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology. 2015;85(22):1930-1936. https://doi.org/10.1212/WNL.0000000000002175
  19. Stanton JED, Chandratheva A, Wilson D, et al. Clinical features distinguish cerebral amyloid angiopathy-associated convexity subarachnoid haemorrhage from suspected TIA. J Neurol. 2020;267(1):133-137.  https://doi.org/10.1007/s00415-019-09558-9
  20. Charidimou A, Boulouis G, Frosch M, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21(8):714-725.  https://doi.org/10.1016/S1474-4422(22)00208-3
  21. Arima H, Tzourio C, Anderson C, et al. PROGRESS Collaborative Group. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke. 2010;41(2):394-396.  https://doi.org/10.1161/STROKEAHA.109.563932
  22. Biffi A, Anderson CD, Battey TW, et al. Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage. JAMA. 2015;314(9):904-912.  https://doi.org/10.1001/jama.2015.10082
  23. Instructions for medical use of the drug Prospekta. State register of medicines. Available 12/16/2023. (In Russ.). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=13b7d400-1129-44a7-b96a-26dc2e9c2fe0
  24. Belova AN, Bogdanov EI, Voznyuk IA, et al. Therapy of moderate cognitive impairment in the early recovery period of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(5):33-39. (In Russ.). https://doi.org/10.17116/jnevro202112105133
  25. Tkacheva ON, Mkhitaryan EA, Kolykhalov IV, et al. Treatment of cognitive, behavioral and mental disorders in patients with vascular dementia: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2023;123(7):41-49. (In Russ.) https://doi.org/10.17116/jnevro202312307141
  26. Shvartsman GI, Skoromets AA, Zhivolupov SA, et al. Therapy of moderate cognitive impairment and asthenia in patients with cerebrovascular pathology: results of a prospective observational study. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;122(8):88-94. (In Russ.). https://doi.org/10.17116/jnevro202212208188
  27. Ostroumova OD, Ebzeeva EYu, Polyakova OA, et al. Treatment of asthenia in patients after acute novel coronavirus infection (COVID-19): results of a multicenter, randomized, double-blind, placebo-controlled clinical trial. Therapy. 2022;8(60):146-157. (In Russ.). https://doi.org/10.18565/therapy.2022.8.146-157
  28. Levin OS, Kovalchuk VV, Putilina MV, et al. Treatment of mild cognitive impairment of various origins in patients with chronic somatic diseases: results of a multicenter open prospective observational program (PARUS). Effective pharmacotherapy. Neurology and psychiatry. 2022;18(43):78-83. (In Russ.).
  29. Solovyova EYu, Kamchatnov PR, Novikova LB, et al. New possibilities for treating mild cognitive impairment and preventing the development of dementia in patients with cerebrovascular diseases. Results of the PRIORITY observation program. Neurology, neuropsychiatry, psychosomatics. 2023;15(1):65-70. (In Russ.). https://doi.org/10.14412/2074-2711-2023-1-65-70

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.